Inhibrx Biosciences, Inc.
INBX evidence brief
What we can confirm
- BioSniper Score:
- 2.0 / 10
- Market Cap:
- $1.66B
- Next Catalyst:
- PDUFA · Apr 14, 2027
What it means
What to watch
Prepared research question
What matters most for INBX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INBX
Inhibrx Biosciences is a clinical-stage biotech developing ozekibart (INBRX-109) for chondrosarcoma and INBRX-106 for solid tumors, with a PDUFA date for ozekibart in April 2027 and a cash position of $133.3M as of 2026-06-30.
Key risk: Cash runway
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 4 clinical trials · 1 catalyst for Inhibrx Biosciences, Inc..
Inhibrx Biosciences is a clinical-stage biotech developing ozekibart (INBRX-109) for chondrosarcoma and INBRX-106 for solid tumors, with a PDUFA date for ozekibart in April 2027 and a cash position of $133.3M as of 2026-06-30.
- Cash & equivalents of $133.3M as of 2026-06-30 [sec].
- Net income of -$36.6M and shareholders' equity of -$53.0M as of 2026-06-30 [sec].
- Ozekibart (INBRX-109) has a PDUFA date of 2027-04-14 [catalyst].
- INBRX-106 Phase 2/3 HexAgon-HN study in HNSCC started 2024-05-14; PFS data expected Q4 2026 [sec · filed 2026-05-11].
- Accumulated deficit of $279.6M as of 2026-03-31 [sec_mda · as of 2026-05-14].
What works
- Ozekibart has a defined PDUFA date (2027-04-14), providing a near-term regulatory catalyst [catalyst].
- INBRX-106 showed promising early results with no treatment-related deaths and predominantly low-grade adverse events in the Phase 2 portion [sec · filed 2026-05-11].
- The company has access to up to an additional $225.0 million in debt financing (Term C/D Loan) at the lenders' discretion [sec_mda · as of 2026-08-13].
What to weigh
- Cash & equivalents of $133.3M as of 2026-06-30 may be limited relative to ongoing R&D and debt obligations [sec].
- Shareholders' equity is negative (-$53.0M as of 2026-06-30), indicating liabilities exceed assets [sec].
- The company has no revenue ($0.0M as of 2026-06-30) and relies entirely on financing and cash reserves [sec].
- Accumulated deficit of $279.6M as of 2026-03-31 reflects sustained net losses [sec_mda · as of 2026-05-14].
From the filings
Quoted directly from source documents.
INBRX-106 Phase 2 safety profile
“No treatment-related deaths were reported in either arm.”
SEC filings · May 11, 2026
Accumulated deficit as of 2026-03-31
“accumulated deficit of $279.6 million”
SEC MD&A · May 14, 2026
Catalyst timeline
- 2027-04-14 · PDUFA: ozekibart — FDA decision on ozekibart (INBRX-109) for unresectable or metastatic conventional chondrosarcoma.
Risks & what to watch (4)›
Key risks
- Cash runway — Cash of $133.3M as of 2026-06-30 may be insufficient to fund operations to profitability without additional financing [sec].
- Negative equity — Shareholders' equity of -$53.0M as of 2026-06-30 indicates liabilities exceed assets [sec].
- No revenue — Total revenue of $0.0M as of 2026-06-30; company depends entirely on financing [sec].
- Clinical trial risk — INBRX-106 Phase 3 data not yet available; PFS data expected Q4 2026 [sec · filed 2026-05-11].
What to watch
- PDUFA decision for ozekibart on 2027-04-14 [catalyst].
- INBRX-106 Phase 2 PFS data expected Q4 2026 [sec · filed 2026-05-11].
- Initiation of Phase 3 portion of HexAgon study in Q3 2026 [sec · filed 2026-05-11].
- Company's ability to draw down additional $225M debt financing [sec_mda · as of 2026-08-13].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Inhibrx Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Inhibrx Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
Net income -$37M
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~182d
No insider transactions in the last 180 days
Catalysts
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 19.9%
- Days to cover
- 10.2
- Shares short
- 2,119,421
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INBX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Inhibrx Biosciences, Inc.?
Inhibrx Biosciences is a clinical-stage biotech developing ozekibart (INBRX-109) for chondrosarcoma and INBRX-106 for solid tumors, with a PDUFA date for ozekibart in April 2027 and a cash position of $133.3M as of 2026-06-30.
What is Inhibrx Biosciences, Inc.'s next catalyst?
Inhibrx Biosciences, Inc.'s next tracked catalyst is a PDUFA event — "PDUFA: ozekibart" — expected April 14, 2027.
Who is the CEO of Inhibrx Biosciences, Inc.?
Mr. Mark Paul Lappe is the chief executive officer of Inhibrx Biosciences, Inc. (INBX).
Where is Inhibrx Biosciences, Inc. headquartered?
Inhibrx Biosciences, Inc. (INBX) is headquartered in La Jolla, CA, United States.
What therapeutic areas does Inhibrx Biosciences, Inc. focus on?
Inhibrx Biosciences, Inc. develops therapies across Oncology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.